Critical care rehabilitation trials: the importance of ‘usual care’

Abstract

Denehy and colleagues conducted a novel randomized controlled trial evaluating a rehabilitation intervention starting in the ICU and continuing through the outpatient setting, with 1 year longitudinal follow-up. While the intervention did not demonstrate improved patient outcomes, this study illustrates important issues regarding ‘usual care’ control groups in clinical trials.

Critical care is evolving beyond a focus on short-term survival to include interventions aimed at reducing survivors’ longer term complications. In this context, ICU-based rehabilitation research and clinical practice is increasingly important. Denehy and colleagues [1] conducted a novel randomized controlled trial evaluating a rehabilitation intervention starting in the ICU and continuing through the outpatient setting, with longitudinal evaluations at ICU and hospital discharge, and 3, 6 and 12 month follow-up. This new study adds to existing prospective controlled trials [2–4] that have evaluated the effect of ICU-based rehabilitation on patient outcomes.

Denehy and colleagues evaluated 150 patients, with an ICU stay ≥5 days, recruited from a single 20-bed medical-surgical ICU in Australia. Patients were randomized to ‘usual care’ physical rehabilitation versus a rehabilitation intervention, prescribed based on physiological principles and standardized physical testing, which commenced in the ICU and continued in the ward and outpatient settings. The primary outcome was the 6 minute walk test (6MWT) at 12 month follow-up, with secondary outcomes including physical function and quality of life measures at ICU and hospital discharge, and 3, 6 and 12 months follow-up. Both groups received sedation as per usual care.

Of the patients enrolled, 92% required intubation and mechanical ventilation, with 55% ventilated at recruitment (ICU day 5). There were no major adverse events and no significant differences in primary or secondary outcomes at 3, 6 and 12 months. The 6MWT was significantly lower in the intervention versus control group at ICU discharge, which may have been due to a higher acuity of illness in the intervention group. Post hoc analysis revealed that improvement in the 6MWT from ICU discharge to 12 months was significantly greater in the intervention versus control group (mean change 292 m versus 219 m; difference 73 m (95% confidence interval 9 to 136)).

To understand the trial results and their generalizability, it is important to examine how rehabilitation was provided in each group and the differences in rehabilitation between the two randomized groups. Denehy and colleagues’ novel rehabilitation intervention has at least two important implications. First, the physiological-based approach to rehabilitation prescription may help enhance reproducibility of the intervention and consistently exercise patients at a higher level. Second, given survivors’ frequent long-lasting neuromuscular and functional impairments [5–8], an intervention spanning the ICU and outpatient settings may be of value. However, notably with this latter point, Denehy and colleagues reported a low rate of participants completing outpatient rehabilitation sessions, with only 41% having at least 70% attendance.

In terms of understanding usual care, on ten occasions during the trial there was prospective measurement of rehabilitation interventions delivered to ICU patients who were not enrolled in the trial [9]. This sampling of usual care revealed that 52% of patients were mobilized in the ICU, including some mechanically ventilated patients sitting out of bed or marching in place [9]. This description of usual care represents substantially greater rehabilitation than delivered in two prior randomized trials (Table 1) [2, 3]. For instance, in Schweickert and colleagues [3], usual care patients received a median of 0 (interquartile range 0 to 0) hours per day of physical and occupational therapy while mechanically ventilated. Moreover, the intensity of usual care rehabilitation in the Denehy and colleagues trial also may have been greater than in other Australian ICUs, based on a one-day, bi-national point prevalence study that demonstrated no mechanically ventilated patients were mobilized out of bed [10].

Table 1 Comparison of in-ICU rehabilitation for intervention and usual care groups in prospective trials

Potentially because of a smaller difference in the dose of rehabilitation between the intervention and control groups in the Denehy and colleagues trial compared to prior prospective controlled trials (Table 1), this new study did not demonstrate a benefit of the novel rehabilitation intervention. However, an important issue highlighted by this trial is the need for standardized measurement and reporting of usual care rehabilitation in clinical trials [11]. Such standardization would allow a better understanding of the difference in rehabilitation intensity between the trial’s randomized groups, and between the trial and prior studies [12]. Moreover, such standardization would allow readers to evaluate the generalizability of the trial’s findings to their own ICUs, based on their local rehabilitation practice patterns [13]. To achieve this goal and help advance rehabilitation research, investigators must discuss this issue and achieve consensus [14].

This trial also highlights the issue of patients’ trajectory of recovery. A post hoc analysis demonstrated that patients in the intervention versus control group had a greater improvement in their 6MWT from ICU discharge to 12 month follow-up. This difference may be important if it reflects a changed trajectory of recovery and translates into survivors reaching clinically meaningful outcomes sooner (for example, earlier return to work). Evaluating these issues may be important for future studies.

In summary, this trial provides a novel longitudinal evaluation of physical rehabilitation delivered across the continuum of patient recovery, highlighting the importance of understanding ‘usual care’ in interpreting trial results. In contrasting this trial with existing studies, we conclude that critically ill patients in both Australia and the US (and likely many other countries) may benefit from the exceptional ‘usual care’ received in the investigators’ study site ICU in Melbourne, Australia.